Stem cell cryopreservation liquid and production method thereof

Abstract

The invention provides stem cell cryopreservation liquid and a preparation method thereof. The stem cell cryopreservation liquid is prepared from the following substances in percentage by volume: 35 to 55 percent of low-sugar type DMEM (Dulbecco's Modified Eagle Medium), 15 to 35 percent of Ultroser G serum replacement, 5 to 20 percent of glycerol, 5 to 10 percent of recombinant human serum albumin and 10 to 20 percent of dextran 40; the stem cell cryopreservation liquid further comprises 4 to 10mg / L of a bFGF (basic Fibroblast Growth Factor) and 250 to 700mmol / L of non-crystalline amorphous trehalose; the invention further provides the production method of the stem cell cryopreservation liquid. The stem cell cryopreservation liquid provided by the invention has the beneficial effects thatthe stem cell cryopreservation liquid is stable and reliable, a differentiation potential of cells can be effectively protected for long time and the cell bioactivity is ensured; exogenous microorganism infection and allergic risks are reduced; the production method is simple to operate and feasible, and has relatively good practical value.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a stem cell cryopreservation solution and a preparation method thereof. Background technique [0002] Stem cell therapy refers to a treatment method in which autologous or allogeneic stem cells are expanded or differentiated in vitro to prepare specific cells required for treatment, and then repair body damage through cell transplantation. At present, a number of clinical application studies of stem cells have been carried out at home and abroad, involving various types of stem cells and various types of diseases. Among them, the most widely studied type of adult stem cells is mesenchymal stem cells, which are mainly derived from bone marrow, adipose tissue and maternal-fetal sources. They have certain multi-directional differentiation potential, anti-inflammatory and immune regulation capabilities. Compared with bone marrow and fat-derived mesenchymal stem cells, maternal-fetal-der...

AI Technical Summary

Problems solved by technology

[0003] At present, most of the cryopreservation solution patents, such as the stem cell cryopreservation solution and stem cell cryopreservation method described in patent application number 200910167171.2 and the serum-free cryopreservation solution and adipose stem cell bank for adipose stem cells described in patent application number 201110227449.8 Establishment, which contains serum or DMSO (dimethyl sulfoxide), can lead to the introduction of serum in the culture medium after cell recovery, and DMSO is slightly toxic to cells

[0004] In addition, according to the current version of the "Chinese Pharmacopoeia", any serum should not be used in the production medium of clinical stem cell preparations. This is because: 1. The composition of serum is complex and the quality is not easy to control, resulting in different manufacturers and different batches of products. The difference is large, which is not conducive to the standardization of cell production; 2. The use of serum is easy to introduce foreign microbial contamination, such as bovine virus, human virus, etc.; 3. Exogenous proteins or other molecular residues in serum may cause patients Allergic reactions, even cause shock, bring hidden dangers to the clinical use of stem cell preparations

Images